Literature DB >> 15980607

Preparation and propagation of amyloid-enhancing factor.

Robert Kisilevsky1.   

Abstract

Amyloid-enhancing factor (AEF) is a biological "activity" that is defined in the context of inflammation-associated amyloidogenesis (AA). When administered intravenously to mice followed by an inflammatory stimulus, such primed mice deposit substantial AA amyloid in spleen within 36-48 h. Since experimental induction of AEF is dependent on amyloidogenic protocols, and rapid AA amyloid induction is dependent on AEF, a strategy for AEF isolation is required to break into this circular process. AEF activity may be prepared from a variety of human forms of amyloid that include tissue containing any of Abeta, AA, ATTR, and AL amyloids. The preparation of an AEF extract from such human tissue is described using 4 M glycerol, which then may be used to induce splenic AA amyloid fibrils in mice as a source for the propagation of additional AEF and/or for the study of amyloidogenesis. The glycerol and AA fibril preparations are stable frozen for many years.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980607     DOI: 10.1385/1-59259-874-9:237

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

Review 1.  Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions.

Authors:  Byron Caughey; Gerald S Baron; Bruce Chesebro; Martin Jeffrey
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

2.  Quantitative tomography of early-onset spontaneous AA amyloidosis in interleukin 6 transgenic mice.

Authors:  Jonathan S Wall; Tina Richey; Amy Allen; Robert Donnell; Steve J Kennel; Alan Solomon
Journal:  Comp Med       Date:  2008-12       Impact factor: 0.982

3.  Cervical cancer of the uterus complicated by renal AA amyloidosis.

Authors:  Hajime Fujisawa; Atsuki Ohashi; Jun Ohta; Naohiro Muraki; Yuta Nakano; Kouhei Sugita; Saori Ishihara; Jiro Kumagai; Toshiyuki Fukutomi; Kiyotaka Nagahama
Journal:  CEN Case Rep       Date:  2020-09-10

4.  Accelerated resolution of AA amyloid in heparanase knockout mice is associated with matrix metalloproteases.

Authors:  Bo Wang; Ying-Xia Tan; Juan Jia; Andreas Digre; Xiao Zhang; Israel Vlodavsky; Jin-Ping Li
Journal:  PLoS One       Date:  2012-07-10       Impact factor: 3.240

5.  Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis.

Authors:  Jonathan S Wall; Emily B Martin; Tina Richey; Alan C Stuckey; Sallie Macy; Craig Wooliver; Angela Williams; James S Foster; Penney McWilliams-Koeppen; Ed Uberbacher; Xiaolin Cheng; Stephen J Kennel
Journal:  Molecules       Date:  2015-04-27       Impact factor: 4.411

6.  A Peptide-Fc Opsonin with Pan-Amyloid Reactivity.

Authors:  James S Foster; Angela D Williams; Sallie Macy; Tina Richey; Alan Stuckey; Daniel Craig Wooliver; Richa Koul-Tiwari; Emily B Martin; Stephen J Kennel; Jonathan S Wall
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561

7.  Evaluation of the effect of D-amino acid incorporation into amyloid-reactive peptides.

Authors:  Emily B Martin; Angela Williams; Tina Richey; Craig Wooliver; Alan Stuckey; James S Foster; Stephen J Kennel; Jonathan S Wall
Journal:  J Transl Med       Date:  2017-12-11       Impact factor: 5.531

8.  Depletion of spleen macrophages delays AA amyloid development: a study performed in the rapid mouse model of AA amyloidosis.

Authors:  Katarzyna Lundmark; Aida Vahdat Shariatpanahi; Gunilla T Westermark
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

9.  Comparative evaluation of p5+14 with SAP and peptide p5 by dual-energy SPECT imaging of mice with AA amyloidosis.

Authors:  Emily B Martin; Angela Williams; Tina Richey; Alan Stuckey; R Eric Heidel; Stephen J Kennel; Jonathan S Wall
Journal:  Sci Rep       Date:  2016-03-03       Impact factor: 4.379

10.  Development of amyloid beta gold nanorod aggregates as optoacoustic probes.

Authors:  Mahmoud G Soliman; Hannah A Davies; Jack Sharkey; Raphaël Lévy; Jillian Madine
Journal:  PLoS One       Date:  2022-03-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.